Merck & Co., Inc. Capital Expenditures
Merck & Co., Inc. (MRK) reported Capital Expenditures of $1.88 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-07
- Merck & Co., Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $893.00M, a 16.88% increase year-over-year.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $991.00M, a 25.38% decline year-over-year.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.03B, a 10.25% increase year-over-year.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $987.00M, a 26.05% increase year-over-year.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $4.11B, a 21.95% increase from fiscal 2024.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $3.37B, a 12.71% decline from fiscal 2023.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.86B, a 11.96% decline from fiscal 2022.
- Merck & Co., Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $4.39B, a 1.35% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $893.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.88B 10-Q · filed 2026-08-07 | $2.92B derived: sum of 3 quarters · filed 2026-08-07 | $3.90B derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $991.00M 10-Q · filed 2026-05-04 | $2.02B derived: sum of 2 quarters · filed 2026-05-04 | $3.01B derived: sum of 3 quarters · filed 2026-05-04 | $3.77B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.03B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.02B derived: sum of 2 quarters · filed 2026-02-24 | $2.78B derived: sum of 3 quarters · filed 2026-08-07 | $4.11B 10-K · filed 2026-02-24 |
| 2025-09-30 | $987.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.75B derived: sum of 2 quarters · filed 2026-08-07 | $3.08B 10-Q · filed 2025-11-05 | $4.02B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $764.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $2.09B 10-Q · filed 2026-08-07 | $3.03B derived: sum of 3 quarters · filed 2026-08-07 | $3.81B derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.33B 10-Q · filed 2026-05-04 | $2.27B derived: sum of 2 quarters · filed 2026-05-04 | $3.05B derived: sum of 3 quarters · filed 2026-05-04 | $3.84B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $937.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.72B derived: sum of 2 quarters · filed 2026-02-24 | $2.51B derived: sum of 3 quarters · filed 2026-02-24 | $3.37B 10-K · filed 2026-02-24 |
| 2024-09-30 | $783.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.57B derived: sum of 2 quarters · filed 2025-11-05 | $2.44B 10-Q · filed 2025-11-05 | $3.42B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $791.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.65B 10-Q · filed 2025-08-05 | $2.64B derived: sum of 3 quarters · filed 2026-02-24 | $3.54B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $861.00M 10-Q · filed 2025-05-02 | $1.85B derived: sum of 2 quarters · filed 2026-02-24 | $2.75B derived: sum of 3 quarters · filed 2026-02-24 | $3.72B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $989.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.89B derived: sum of 2 quarters · filed 2026-02-24 | $2.86B derived: sum of 3 quarters · filed 2026-02-24 | $3.86B 10-K · filed 2026-02-24 |
| 2023-09-30 | $902.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.87B derived: sum of 2 quarters · filed 2024-11-06 | $2.87B 10-Q · filed 2024-11-06 | $4.02B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $965.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.97B 10-Q · filed 2024-08-05 | $3.12B derived: sum of 3 quarters · filed 2025-02-25 | |
| 2023-03-31 | $1.01B 10-Q · filed 2024-05-03 | $2.16B derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $1.15B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $4.39B 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $3.24B 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $4.45B 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |